CTOs on the Move

Gateway Family House

www.gatewaypathways.com

 
Gateway Family House is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

QueensCare Family Clinics

QueensCare Family Clinics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. QueensCare Family Clinics is based in Los Angeles, CA. You can find more information on QueensCare Family Clinics at www.queenscare.org

Donor Alliance

Donor Alliance is the federally-designated, Association of Organ Procurement Organizations (AOPO) and American Association of Tissue Banks (AATB) accredited, non-profit organ procurement organization serving Colorado and most of Wyoming. As a recognized leader in facilitating the donation and recovery of transplantable organs and tissues, Donor Alliance`s mission is to save lives through organ and tissue donation and transplantation. To achieve this mission, Donor Alliance employs effective family approach and recovery programs in more than 100 hospitals. Donor Alliance also inspires the public to register as organ and tissue donors through community partnerships, public outreach and education campaigns throughout its donation service area.

Revolution Health Group

Revolution Health Group LLC is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Biosystems, part of Life Technologies

Applied Biosystems, part of Life Technologies is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Applied Biosystems, part of Life Technologies is based in San Mateo, CA. You can find more information on Applied Biosystems, part of Life Technologies at www.appliedbiosystems.com

Acucela

Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.